Teknos Oy, Helsinki factory, Takkatie 3, P.O.Box 107, 00371 Helsinki, Finland (Suomija). - search results

United States - English - NLM (National Library of Medicine)

menostar- estradiol patch

bayer healthcare pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 14 ug in 1 d - menostar is indicated for: menostar is contraindicated in women with any of the following conditions: risk summary menostar is not indicated for use in pregnancy. there are no data with the use of menostar in pregnant women, however, epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to combined hormonal contraceptives (estrogens and progestins) before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary estrogens are present in human milk and can reduce milk production in breast-feeding females. this reduction can occur at any time but is less likely to occur once breast-feeding is well-established. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for menostar and any potential adverse effects on the breastfed child from menostar or from the underlying maternal condition. menostar is not indicated for use in pediatric patients. clinical studies have not been conducted in the pediatric population. a total of 417 postmenopausal women 61 to 79 years old, with an intact uterus, participated in the osteoporosis trial. more than 50 percent of women receiving study drug, were 65 years of age or older. efficacy in older (≥ 65 years of age) and younger (<65 years of age) postmenopausal women in the osteoporosis treatment trial was comparable both at 12 and 24 months. safety in older (≥ 65 years of age) and younger (<65 years of age) postmenopausal women in the osteoporosis treatment trial was also comparable throughout the study. in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.2)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.2)] . in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.3)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.3)].

Australia - English - Department of Health (Therapeutic Goods Administration)

menosupercare

universal pharmaceuticals pty ltd - borax,calcium citrate tetrahydrate,colecalciferol,colloidal anhydrous silica,glycine max,heavy magnesium oxide,hydroxyapatite,manganese amino acid chelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

menosupport

fit-bioceuticals pty ltd - actaea racemosa, quantity: 3.08 mg (equivalent: actaea racemosa, qty 20 mg; equivalent: triterpene glycosides calc 27-deoxyactein (of actaea racemosa), qty 77 microgram); lepidium meyenii, quantity: 150 mg (equivalent: lepidium meyenii, qty 1.5 g); salvia officinalis, quantity: 272.73 mg (equivalent: salvia officinalis, qty 1.5 g; equivalent: thujone, qty 4.09 mg); ziziphus jujuba var. spinosa, quantity: 171.43 mg (equivalent: ziziphus jujuba var. spinosa, qty 3 g); pinus pinaster, quantity: 15 mg (equivalent: procyanidins (of pinus pinaster), qty 9.75 mg; equivalent: pinus pinaster, qty 15000 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; povidone; carnauba wax; chlorophyllin-copper complex; calcium hydrogen phosphate dihydrate; crospovidone; colloidal anhydrous silica; macrogol 8000 - traditionally used in western herbal medicine to decrease/reduce/relieve excessive perspiration/sweating ; traditionally used in western herbal medicine to decrease/reduce/relieve nervous tension/unrest ; traditionally used in western herbal medicine to helps decrease/reduce/relieve night sweats associated with menopause ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of menopause ; traditionally used in western herbal medicine to decrease/reduce/relieve hot flushes associated with menopause